PTK2 and acute myeloid leukemia: RUNX1 mutations in some high-risk AML patients help in explaining the high FAK expression in these cases with a mechanism involving two negative FAK regulators, i.e., miRNAs hsa-let7a-2-3p and hsa-miR-135a-5p